Direct compression of monopotassium (2R,3S)-isocitrate at low drug loadings is initiated by screening the API through a 500 µm conical mill fitted with a round impeller at 1,500 rpm, discharging into a bin blender. The bulk API is released with chiral purity not less than 98.0% by validated chiral HPLC before blending. The salt is first blended with microcrystalline cellulose PH102 at a 1:3 w/w ratio for 12 min at 10 rpm; this pre-blend step reduces agglomerate persistence and prevents localized pockets of unrecovered API. Spray-dried lactose monohydrate, croscarmellose sodium, and colloidal silicon dioxide are then added, followed by a final lubrication stage with 0.5 wt% sodium stearyl fumarate for 3 min. Particle size distribution of the API is controlled to a D90 below 120 µm because larger crystals create content uniformity risk in low-dose tablets. Blend uniformity testing according to USP <905> generally requires 10 sampling points across the discharge profile; acceptance is 90.0–110.0% label claim with an RSD not exceeding 5.0%. On a 16-station rotary tablet press equipped with 8 mm round B-tooling, precompression force is typically set at 4–6 kN and main compression force at 10–18 kN, yielding tablet hardness between 60 N and 90 N. Friability assessed by USP <1216> should remain below 0.8% after 100 revolutions. Compression rooms are maintained at 20–25 °C and 40–50% RH; excursions above 60% RH can increase sticking and picking due to moisture uptake at the salt crystal surfaces. Tablet press speed is reduced to 30–40 rpm when electrostatic charging produces powder adhesion to the die wall; stainless steel tooling with a chromium nitride coating is preferred over plain steel to reduce buildup. Published data for this specific configuration are limited, so force-displacement profiles and moisture sorption isotherms should be generated before process validation.

Why Does Wet Granulation Require a Non-Aqueous or Buffered Binder for This API?

Wet granulation imposes a solvent-selection constraint because the potassium salt dissolves in free water, producing a sticky granulating mass that can undergo particle size enlargement by uncontrolled crystal bridging during tray drying. Fluid-bed granulation with a hydroalcoholic binder composed of 70–85% ethanol and 15–30% water containing 2–5% povidone K30 is used. The binder is sprayed at 8–15 g/min into a top-spray fluid bed charged with a 5 kg dry blend. Inlet air temperature is set between 40 °C and 55 °C, product temperature is held below 35 °C, and exhaust relative humidity is maintained below 20% to avoid dissolution of the salt. Granule growth is tracked by laser diffraction; target d50 after drying is 120–180 µm with a span below 1.8. If the granulation end-point is missed and mass moisture exceeds 2.5% by loss on drying, the dried granules show increased friability and capping during compression. Aqueous granulation may be feasible only when the aqueous phase is buffered to pH 4.0–5.0 with citrate buffer and when processing time is kept below 30 min; the use of potassium-containing buffer systems requires accounting for total potassium content in the finished dosage form. After drying, granules are milled through a 1.0 mm screen and blended with extragranular disintegrant and lubricant. The process is completed under controlled room temperature; granule moisture content is released at not more than 2.0% by Karl Fischer titration. pH excursions above 6.5 should be avoided during solution processing unless forced degradation studies show configurational stability. Published formulation-specific data for this salt remain limited, so pH and solvent composition must be confirmed by forced degradation studies that quantify isocitrate isomerization products.

For low-dose capsule manufacturing, monopotassium (2R,3S)-isocitrate is incorporated through a stepwise trituration sequence rather than by direct mixing of the neat API with the final filler. The API and lactose monohydrate 200 mesh are passed three times through a 500 µm screen and then mixed in a V-blender at 25 rpm for 15 min; the first intermediate is diluted stepwise with microcrystalline cellulose PH102 and pregelatinized starch to final batch size. The final blend contains 0.5–2.0 wt% API, 0.25 wt% colloidal silicon dioxide, and 0.5 wt% magnesium stearate. Powder flow is measured by USP <1174>; a Carr index below 20% and a Hausner ratio below 1.25 are targeted before filling. Capsule fill weight is controlled on a dosator-type capsule machine at 40,000–80,000 capsules/h; fill weight variation is monitored at 10–15 min intervals. Content uniformity for the encapsulated product follows USP <905>; acceptance values are calculated for 10 individual capsules at the beginning, middle, and end of the run. If density stratification occurs during hopper hold times longer than 2 h, routine sampling at the hopper discharge is increased and fill weight corrected. The use of a low-shear in-bin agitator is often required when ambient relative humidity exceeds 55%; without agitation, the potassium salt may adsorb surface moisture and reduce flow. Finished capsules are packaged with a desiccant canister and sealed in aluminum blisters; storage at 25 °C/60% RH for 12 months is typical for stability evaluation. Published data for this specific configuration is limited, but the described trituration practice follows standard low-dose blending methodology.

Terminal Sterilization and pH Drift Boundaries in Aqueous Parenteral Solutions

Aqueous injectable solutions of monopotassium (2R,3S)-isocitrate are compounded in Water for Injection, with the pH adjusted to 4.8–5.5 using dilute potassium hydroxide or citric acid. The solution is blanketed with nitrogen during compounding because the TCA-cycle intermediate is susceptible to oxidation at neutral-to-basic pH and under dissolved oxygen load. Tonicity is adjusted with sodium chloride or mannitol to 270–310 mOsm/kg; the potassium input from the API must be included in the total electrolyte calculation to avoid inadvertent hyperkalemic load in renal-impaired patients. The formulated bulk is filtered through 0.22 µm polyethersulfone filter capsules at 5–10 L/min per 10-inch cartridge, followed by filling into Type I borosilicate glass vials. Terminal sterilization is evaluated through USP <1222> and ICH Q3D risk assessment; a 121 °C for 15 min autoclave cycle may be tolerated only if forced degradation studies show no unacceptable isomerization or decarboxylation. Parenteral particulate matter is controlled per USP <790>; subvisible particle counts for the finished solution are verified using light obscuration with limits of ≤ 6,000 particles per container at ≥ 10 µm and ≤ 600 at ≥ 25 µm. If particulates trend upward after terminal sterilization, pH is re-tested and the container filling headspace is sampled for oxygen. Polyvalent cations such as calcium or magnesium should not be used as tonicity adjusters in the same solution unless compatibility studies confirm absence of insoluble complex formation. Published data for autoclave stability of this specific salt are limited; therefore, aseptic filtration at 0.22 µm without terminal steam sterilization is the conservative processing route until product-specific thermal degradation kinetics are established.

When Lyophilized Injection Requires Crystalline Bulking Agents and Collapse Temperature Mapping

Freeze-dried monopotassium (2R,3S)-isocitrate for injection is prepared by combining the API with 4–6% w/v mannitol as a crystalline bulking agent and 0.5–1.0% w/v sucrose as an amorphous stabilizer. The formulation is filled into 10 mL Type I glass vials and loaded onto a lyophilizer shelf pre-cooled to 5 °C. The primary drying cycle is designed after freeze-dry microscopy identifies the collapse temperature; for mannitol-rich systems, shelf temperature is typically held at -30 °C to -25 °C under 80–120 mTorr chamber pressure for 24–36 h. Annealing at -15 °C for 2 h is introduced after free ice crystallization to reduce vial-to-vial heterogeneity and promote mannitol crystallization. Primary drying is terminated when product temperature probes and comparative pressure measurement indicate the ice front has disappeared; secondary drying at 25–30 °C for 4–6 h reduces residual moisture to below 1.0% by Karl Fischer. Residual moisture above 1.5% can depress the glass transition of the amorphous phase and increase the risk of collapse during storage. Stoppering is performed under vacuum or dry nitrogen; moisture ingress rate across the lyophilization stopper is verified by container closure integrity testing per USP <1207>. The freeze-dried cake should be uniform, with no melt-back or shrinkage at the vial wall. Reconstitution time with 5 mL Sterile Water for Injection should be below 30 s; pH and osmolality after reconstitution are checked against the solution specification. Published formulation data for this specific salt under lyophilization are limited, so the thermal properties of each lot should be mapped by differential scanning calorimetry before freeze-drying.

When pediatric or geriatric dosing requires a flexible oral format, bottom-spray fluid-bed granulation is used to prepare monopotassium (2R,3S)-isocitrate granules for single-dose sachets. A dry powder mixture of the API, mannitol, xylitol, and hydroxypropyl cellulose is fluidized at 35–45 °C inlet air temperature; the binder solution, consisting of 5% hydroxypropyl cellulose in a 60:40 v/v ethanol-water mixture, is sprayed at 6–10 g/min to build granules to a d50 of 150–220 µm. The granulation is dried to 1.0–2.0% moisture and passed through an oscillating granulator fitted with a 1.0 mm screen. Disintegration time in USP <701> is targeted below 5 min; dissolution using USP <711> apparatus II at 50 rpm in 900 mL of pH 4.5 acetate buffer is used for release testing. Granules are filled into single-dose sachets under nitrogen-flushed conditions; the package is sealed with a foil laminate having a moisture vapor transmission rate below 0.05 g/m²/day. The potassium salt should not be combined with strongly alkaline pH modifiers such as sodium carbonate in this format because local pH excursions above 6.5 during dissolution can accelerate degradation and produce free acid conversion. In-process controls on granule moisture and particle size are required at the start, middle, and end of each granulation run because batch-to-batch variability in fluidization pattern can shift the d50 outside the specified range. Published data for this specific granule composition are limited; the final buffer species and concentration should be confirmed by stability-indicating assay development.